| 引用本文: | 丁华敏,钱淑雨,苏锦文,潘忙忙,王昕,顾智淳,张弛.基于Granada-Ⅱ分类法评价非维生素K拮抗剂口服抗凝药物用于非瓣膜性心房颤动药物相关问题[J].中国现代应用药学,2025,42(11):132-139. |
| dinghuamin,qianshuyu,sujinwen,panmangmang,wangxin,guzhichun,zhangchi.Evaluation of Drug-Related Problems of NOACs in Patients with Non-Valvular Atrial Fibrillation Based on Granada-Ⅱ Classification Method[J].Chin J Mod Appl Pharm(中国现代应用药学),2025,42(11):132-139. |
|
| 摘要: |
| 目的 探讨非维生素K拮抗剂口服抗凝药(NOAC)用于非瓣膜性心房颤动(NVAF)患者的药物相关问题(DRPs),以促进临床合理使用。方法 利用院内信息系统,抽取2023年度心血管内科使用利伐沙班、艾多沙班、达比加群酯的NVAF患者病例共276份,以药品说明书、指南、专家共识为基础,采用Granada-Ⅱ分类法对患者使用上述三种药物的必要性(包括DRP1和DRP2)、有效性(包括DRP3和DRP4)、安全性(包括DRP5和DRP6)进行评价。结果 纳入的276例病例,发生DRPs共计95例(34.42%),包括有效性DRP4 58例(21.01%),安全性DRP5 29例(10.51%)和DRP6 8例(2.89%),均未发生DRP1、DRP2、DRP3的情况。结论 该院心血管内科NVAF患者使用NOACs的主要不合理为有效性问题,需加强药学干预,促进合理用药。 |
| 关键词: 利伐沙班 艾多沙班 达比加群酯 非瓣膜性心房颤动 药物相关问题 Granada-Ⅱ分类法 回顾性分析 合理用药 |
| DOI： |
| 分类号: |
| 基金项目:上海市浦东新区卫生系统优秀青年医学人才培养计划(项目编号PWRq2020-25)；上海市浦东新区科技发展基金事业单位民生科研专项医疗卫生项目(项目编号PKJ2023-Y17) |
|
| Evaluation of Drug-Related Problems of NOACs in Patients with Non-Valvular Atrial Fibrillation Based on Granada-Ⅱ Classification Method |
|
dinghuamin1, qianshuyu1, sujinwen1, panmangmang2, wangxin2, guzhichun3, zhangchi2
|
|
1.Shanghai Punan Hospital of Pudong New District;2.Ren Ji Hospita;3.Shanghai Punan Hospital of Pudong New District， Ren Ji Hospita
|
| Abstract: |
| ABSTRACT: OBJECTIVE To investigate the drug- related problems （DRPs） of NOACs in patients with non- valvular atrial fibrillation （AF）, and to promote the rational use of rivaroxaban, edoxaban and dabigatran in the clinic. METHODS A total of 256 medical records of inpatients with non- valvular atrial fibrillation treated with rivaroxaban, edoxaban and dabigatran in the Department of Cardiology in the hospital in 2023 were selected. Based on the drug manual of relevant guidelines，consensus，and literature，the Granada Ⅱ classification method was used to evaluate the necessity （including DRP1 and DRP2）, effectiveness （including DRP3 and DRP4）, and safety （including DRP5 and DRP6）of using the three drugs mentioned above in patients. RESULTS A total of 276 patients with non- valvular atrial fibrillation treated with rivaroxaban, edoxaban and dabigatran were included，with 95cases （34.42%） of DRPs, including 58 cases （21.01%） of DRP4，29cases （10.51%）of DRP5, and 8 cases（2.89%）of DRP6. CONCLUSION DRPs in patients with non-valvular atrial fibrillation in the Department of Cardiology in the hospital are mainly the effectiveness. It is necessary to strengthen training and intervention on rational drug use to promote the rational use of NOACs in patients with non- valvular atrial fibrillation. |
| Key words: rivaroxaban edoxaban dabigatran non- valvular atrial fibrillation drug- related problems Granada-Ⅱ classification method retrospective analysis rational drug use |
